4
MARKET OVERVIEW
Provides a snapshot of current market scenario, value chain context, and factors impacting competitive intensity.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMICS INDICATORS
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN EUROPEAN HEALTHCARE INDUSTRY
5.2.4
TRENDS IN EUROPEAN MEDICAL DEVICE INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, FOR LEUKAPHERESIS PRODUCTS, BY TYPE,
5.6.2
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, FOR LEUKAPHERESIS PRODUCTS, BY APPLICATION,
5.6.3
AVERAGE SELLING PRICE TREND, FOR LEUKAPHERESIS PRODUCTS, BY COUNTRIES, 2023-2025
5.6.4
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, FOR LEUKOPAKS, BY TYPE,
5.6.5
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, FOR LEUKOPAKS, BY APPLICATION,
5.7.1
IMPORT SCENARIO (HS CODE 842119)
5.7.2
EXPORT SCENARIO (HS CODE 842119)
5.8
KEY CONFERENCES AND EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.11
SUCCESS STORIES AND REAL-WORLD APPLICATIONS
5.12
IMPACT OF 2025 US TARIFF – EUROPE LEUKAPHERESIS MARKET
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRIES
5.12.5
IMPACT ON END-USE INDUSTRIES
6
STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
CENTRIFUGAL-BASED LEUKAPHERESIS
6.1.2
MEMBRANE-BASED LEUKAPHERESIS
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
INLINE CELL COUNTING AND PRODUCT ANALYTICS
6.2.2
CLOSED-SYSTEM CELL PROCESSING
6.3
ADJACENT TECHNOLOGIES
6.3.1
STEM CELL APHERESIS SYSTEMS AND MOBILIZATION SUPPORT
6.3.2
THERAPEUTIC PLASMA EXCHANGE/IMMUNOADSORPTION SYSTEMS
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.7
IMPACT OF AI/GEN AI ON EUROPE LEUKAPHERESIS MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN EUROPE LEUKAPHERESIS MARKET
6.7.3
CASE STUDIES OF AI IMPLEMENTATION IN THE EUROPE LEUKAPHERESIS MARKET
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN EUROPE LEUKAPHERESIS MARKET
7
REIMBURSEMENT AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
REGIONAL REIMBURSEMENT ANALYSIS
7.3
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES IN EUROPE LEUKAPHERESIS MARKET
9
EUROPE LEUKAPHERESIS MARKET, BY TYPE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME, THOUSAND UNITS)
9.2
LEUKAPHERESIS DISPOSABLES
9.3
LEUKAPHERESIS DEVICES
9.3.1
CENTRIFUGAL DEVICES
9.3.2
MEMBRANE SEPARATORS
10
EUROPE LEUKAPHERESIS MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
10.2
RESEARCH APPLICATIONS
10.3
THERAPEUTIC APPLICATIONS
11
EUROPE LEUKAPHERESIS MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
11.2
BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
11.3
ACADEMIC & RESEARCH INSTITUTES
11.4
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.5
HOSPITALS & TRANSFUSION CENTERS
12
EUROPE LEUKOPAKS MARKET, BY TYPE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME, THOUSAND UNITS)
12.3
NON-MOBILIZED LEUKOPAKS
13
EUROPE LEUKOPAKS MARKET, BY INDICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
13.2
ACUTE LYMPHOCYTIC LEUKEMIA
13.4
NON-HODGKIN’S LYMPHOMA
13.5
CHRONIC LYMPHOCYTIC LEUKEMIA
13.7
HEPATOCELLULAR CARCINOMA
14
EUROPE LEUKOPAKS MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
14.2
ACADEMIC & RESEARCH INSTITUTES
14.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.4
CONTRACT RESEARCH ORGANIZATIONS
15
EUROPE LEUKAPHERESIS MARKET, BY COUNTRIES (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUMN, THOUSAND UNIT)
16.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
16.3
REVENUE SHARE ANALYSIS OF KEY PLAYERS (2023-2025)
16.4
EUROPE LEUKAPHERESIS MARKET SHARE ANALYSIS,
16.4
EUROPE LEUKOPAKS MARKET SHARE ANALYSIS,
16.5
EUROPE LEUKAPHERESIS MARKET, BRAND/PRODUCT COMPARATIVE ANALYSIS
16.6
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 (EUROPE LEUKAPHERESIS MARKET)
16.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
16.6.5.1
COMPANY FOOTPRINT
16.6.5.2
COUNTRY FOOTPRINT
16.6.5.4
APPLICATION FOOTPRINT
16.7
COMPANY EVALUATION MATRIX: STARTUPS/SME’S, 2025 (EUROPE LEUKAPHERESIS MARKET)
16.7.1
PROGRESSIVE COMPANIES
16.7.2
RESPONSIVE COMPANIES
16.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SME’S,
16.7.5.1
DETAILED LIST OF KEY STARTUPS/SME’S
16.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME’S
16.6
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 (EUROPE LEUKOPAKS MARKET)
16.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
16.6.5.1
COMPANY FOOTPRINT
16.6.5.2
COUNTRY FOOTPRINT
16.6.5.4
INDICATION FOOTPRINT
16.8
EUROPE LEUKAPHERESIS MARKET: VALUATION AND FINANCIAL MATRICS OF KEY PLAYERS
16.9
COMPETITIVE SITUATION AND TRENDS
16.9.4
OTHER DEVELOPMENTS
17.1
KEY PLAYERS (LEUKAPHERESIS MARKET)
17.1.3
HAEMONETICS CORPORATION
17.1.8
BAXTER INTERNATIONAL INC.
17.2
OTHER PLAYERS (LEUKAPHERESIS MARKET)
17.2.1
IMMUNE THERAPY HOLDINGS AB
17.2.3
BIOHOPE SCIENTIFIC SL
17.2.4
CALTAG MEDSYSTEMS LTD.
17.3
KEY PLAYERS (LEUKOPAKS MARKET)
17.3.2
GRIFOLS BIO SUPPLIES
17.3.3
CHARLES RIVER LABORATORIES
17.3.4
CELLEX CELL PROFESSIONALS
17.3.5
STEMCELL TECHNOLOGIES
17.3.7
DISCOVERY LIFE SCIENCES
17.3.8
NHS BLOOD AND TRANSPLANT
17.4
OTHER PLAYERS (LEUKOPAKS MARKET)
17.4.3
TRINA BIOREACTIVES AG (SWITZERLAND)
17.4.4
FIRST CHOICE BIO INC.
*THE LIST OF COMPANIES MENTIONED ABOVE IS INDICATIVE ONLY. THE LIST OF COMPANIES IS NOT EXHAUSTIVE AND MIGHT CHANGE DURING THE STUDY.
18.1.1.1
KEY DATA FROM SECONDARY SOURCES
18.1.2.1
KEY DATA FROM PRIMARY SOURCES
18.1.2.2
KEY PRIMARY PARTICIPANTS
18.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
18.1.2.4
KEY INDUSTRY INSIGHTS
18.2
MARKET SIZE ESTIMATION
18.2.1
BOTTOM-UP APPROACH
18.2.3
BASE NUMBER CALCULATION
18.3
MARKET FORECAST APPROACH
18.6
RESEARCH ASSUMPTIONS
18.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
19.1
INSIGHTS OF INDUSTRY EXPERTS
19.3
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.4
AVAILABLE CUSTOMIZATION
19.4.1
GEOGRAPHIC ANALYSIS
19.4.2
COUNTRY-LEVEL MARKET SHARE ANALYSIS
19.4.3
COMPANY INFORMATION
19.4.5
COUNTRY-LEVEL VOLUME ANALSYSIS
19.4.6
BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
19.4.7
ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
Growth opportunities and latent adjacency in Europe Leukapheresis Market